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tool in vascular secondary health care practice.
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The authors have studied a cohort from the SMART (Secondary
Manifestations of ARTerial Disease) study for the purpose of identi-
fying risk factors associated with stroke, myocardial infarction, and
death in patients with peripheral arterial disease. They suggest that
identifying very high risk patients could lead to interventions that
would reduce cardiovascular morbidity andmortality. Eight hundred
patients were identified who met their criteria, estimated to be about
10% of the patients recruited in the SMART study at the time of
enrollment. They were able to construct a scoring system based on
eight variables that separates peripheral arterial disease patients into
four risk categories. The very high risk patients had a 10% risk of
stroke, myocardial infarction, or death at one year, and a 28% risk ofsystem developed for peripheral arterial disease patients and could be
a valuable screening tool for clinicians.
Although the study population was heterogeneous, all pa-
tients were from the Netherlands and the scoring system may not
apply to other populations across the world. The SMART study is
prospective and the authors have appropriately utilized statistical
modeling, but this scoring system will require validation on other
populations to confirm the authors’ findings.
The authors’ intent was to develop a scoring system that
would identify very high risk patients whomight benefit frommore
aggressive evaluation and treatment. They suggest that secondary
cardiovascular events (stroke, myocardial infarction, and death)
might be reduced with more extensive work-up of the very high
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Volume 50, Number 6 Healy 1377risk patients identified in their study. By indentifying severe carotid
stenosis, advanced coronary artery disease, and cardiac arrhyth-
mias, such very high risk patients might benefit from aggressive
intervention. Just as the Goldman criteria helped to identify clinical
criteria that predicted perioperative cardiac risk, the authors’ scor-patients in need of more extensive cardiovascular evaluation. While
intuitively this may seem logical, it is unclear whether intervention
in asymptomatic patients would alter outcomes. Caution should be
used in applying the authors’ scoring system until more is known
about the results of an aggressive approach to the management ofing system could assist clinicians by identifying very high risk the very high risk group that they have identified.
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